Please Wait...

Nick Lenares

Main profile

Chief Product Architect

Nick Lenares is a lead product architect with BioClinica, and is chiefly responsible for software design and development around the Optimizer product suite and more recently the upcoming EDA product. Nick has worked closely with some of the world's top biostatisticians and clinical supply professionals to gain a detailed understanding of current clinical supply chain challenges, and to invent and discover new solutions. Among many other innovations, Nick has authored a novel probabilistic resupply algorithm as well as the world's first unpredictable site demand forecaster in Optimizer.

Blogs

Following on several speaking engagements this year, I was recently interviewed by Mark Uehling of ClinPage to discuss some current developments in the field of clinical supply simulation and optimization. Because of Mark’s propensity to research and present (sometimes dry) information in unique and interesting ways, interviews with ClinPage are always fun - and this one was no exception! We covered topics ranging from the adoption of simulation tools in large pharmaceuticals (hint: > 50%) to the wide variety of benefits that companies realize from simulation beyond just dollar savings on clinical supply.
The 2010 Optimizer User Conference recently ended and I am happy to report a surge in discussion around technology for clinical trial supply planning. I think this speaks well to the growth of the Optimizer product and greater acceptance of the application of more sophisticated tools to the clinical supply planning process in general. There were a number of roundtable discussions and open training sessions, which were as valuable for me as I believe they were for the attendees.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

RT @DrugInfoAssn: What has been the biggest takeway for your organization so far? Tweet @ us using #DIA2017
bioclinica (Yesterday)
"Q" on #RBM & Total Quality Mgmt? @Kristin_Mauri has "A" @DrugInfoAssn #DIA2017 https://t.co/MqCxkmAfa0
bioclinica (Yesterday)
Kristen Mauri shows the @DIA audience the value of risk based monitoring https://t.co/ssJCfc9gQ5
bioclinica (Yesterday)
Innovation Theater Kristin Mauri of @bioclinica presenting on RBM & TQM @DrugInfoAssn #DIA2017 https://t.co/zsGroQcpiU
bioclinica (Yesterday)
Innovation Theater @DrugInfoAssn #DIA2017 Kicking off at 1. Perspectives on risk-based monitoring and TQM. https://t.co/mH6Npg0kD4
bioclinica (Yesterday)
RT @Xtalks: How Improving Site Payments Can Make You the Sponsor/CRO of Choice Tune in for this live webinar with @bioclinica https://t.co/…
bioclinica (Yesterday)

Latest Blogs: